Your browser is no longer supported. Please, upgrade your browser.
Settings
BIOC Biocept, Inc. daily Stock Chart
BIOC [NASD]
Biocept, Inc.
Index- P/E- EPS (ttm)-2.17 Insider Own2.20% Shs Outstand17.49M Perf Week0.00%
Market Cap37.78M Forward P/E- EPS next Y-0.65 Insider Trans197.87% Shs Float17.42M Perf Month6.40%
Income-18.40M PEG- EPS next Q-0.21 Inst Own15.50% Short Float20.18% Perf Quarter169.93%
Sales3.20M P/S11.81 EPS this Y37.50% Inst Trans- Short Ratio1.00 Perf Half Y266.10%
Book/sh0.04 P/B54.00 EPS next Y- ROA-307.40% Target Price- Perf Year70.08%
Cash/sh0.26 P/C8.21 EPS next 5Y40.00% ROE- 52W Range0.49 - 3.39 Perf YTD178.71%
Dividend- P/FCF- EPS past 5Y35.10% ROI- 52W High-36.28% Beta-
Dividend %- Quick Ratio1.20 Sales past 5Y398.00% Gross Margin- 52W Low340.82% ATR0.17
Employees42 Current Ratio1.30 Sales Q/Q550.00% Oper. Margin- RSI (14)52.99 Volatility7.21% 8.10%
OptionableYes Debt/Eq0.00 EPS Q/Q63.30% Profit Margin- Rel Volume0.11 Prev Close2.23
ShortableYes LT Debt/Eq0.00 EarningsMar 07 AMC Payout- Avg Volume3.53M Price2.16
Recom- SMA20-1.62% SMA5010.83% SMA20099.85% Volume398,056 Change-3.14%
Jun-06-16Initiated ROTH Capital Buy $1.20
Aug-19-15Initiated H.C. Wainwright Buy $4
Jun-03-14Initiated Aegis Capital Buy $16
Mar-23-17 04:12PM  BIOCEPT INC Files SEC form 8-K, Shareholder Director Nominations
09:30AM  Biocept and OvaScience Post Gains Amid Investor Speculation Accesswire
Mar-20-17 08:05AM  Biocept Announces Revised Presentation Time at the 27th Annual Oppenheimer Healthcare Conference PR Newswire
Mar-15-17 08:05AM  Biocept to Present at the 27th Annual Oppenheimer Healthcare Conference PR Newswire
Mar-14-17 11:38AM  Couple sue pharma giant for work that led to prison in China
08:05AM  Biocept and Catalyst Pharmaceuticals Collaborate to Provide Liquid Biopsy Testing for Small Cell Lung Cancer to Patients with Lambert Eaton Myasthenic Syndrome (LEMS) PR Newswire
Mar-11-17 02:55AM  Trump's choice for FDA has ties to Wall Street, drug makers
Mar-10-17 07:21PM  Trump picks former FDA official to head food and drug agency
Mar-08-17 08:05AM  Biocept to Present at the 29th Annual ROTH Conference PR Newswire
Mar-07-17 04:06PM  BIOCEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -5.04%
04:05PM  Biocept Reports Fourth Quarter and Full Year 2016 Financial Results PR Newswire
07:07AM  Q4 2016 Biocept Inc Earnings Release - After Market Close
Feb-21-17 08:05AM  Biocept to Release 2016 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 7, 2017 PR Newswire
Feb-15-17 08:05AM  Biocept Appoints Michael Terry Senior Vice President Commercial Operations PR Newswire
Feb-09-17 08:12AM  BIOCEPT INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits +29.59%
08:05AM  Biocept's CEO Issues Letter to Stockholders PR Newswire
Feb-08-17 11:57AM  GSK warns profits to be hit by generic drugs competition +7.64%
Feb-06-17 08:05AM  Biocept to Present at the 19th Annual BIO CEO and Investor Conference PR Newswire
Jan-25-17 09:01AM  BIOCEPT INC Files SEC form 8-K, Other Events -5.33%
Jan-19-17 12:26PM  ETFs with exposure to Biocept, Inc. : January 19, 2017 +9.27%
09:05AM  Biocept Awarded Patent in Australia for the Use of Antibodies in Microchannels to Capture Circulating Tumor Cells and Other Rare Cells PR Newswire
Jan-13-17 09:30AM  Latest Reports on Biocept and Apricus Biosciences as President Trump's Comments Put Pressure on Drug Manufacturers Accesswire
Jan-10-17 03:30PM  Tuesdays Top Biopharma Movers +77.45%
09:36AM  Biocept Secures In-Network Provider Agreement with Blue Cross Blue Shield of Texas PR Newswire
Dec-27-16 08:05AM  Columbia University Medical Center Sponsors Clinical Study Using Biocept's Liquid Biopsy Platform to Evaluate Cerebrospinal Fluid of Breast Cancer Patients for Metastatic Biomarkers PR Newswire
Dec-08-16 08:05AM  Clinical Utility of Biocept's Liquid Biopsy Platform Demonstrated in Study Results Presented at the 2016 San Antonio Breast Cancer Symposium PR Newswire
Dec-07-16 09:45AM  Biocept Presents Robust Analytical Validation Study Results for its PD-L1 Liquid Biopsy Test at the 17th IASLC World Conference on Lung Cancer PR Newswire
08:04AM  Teladoc November Visits Set Record: Why is Stock Suffering?
Dec-05-16 11:51AM  ETFs with exposure to Biocept, Inc. : December 5, 2016
Dec-02-16 05:11PM  BIOCEPT INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Trans
Nov-21-16 08:05AM  Biocept to Present at the LD Micro Main Event PR Newswire
Nov-18-16 01:04PM  BIOCEPT INC Financials
Nov-14-16 12:56PM  ETFs with exposure to Biocept, Inc. : November 14, 2016
Nov-10-16 04:09PM  BIOCEPT INC Files SEC form 10-Q, Quarterly Report +6.96%
11:46AM  Biocept, Inc. :BIOC-US: Earnings Analysis: Q3, 2016 By the Numbers : November 10, 2016
Nov-09-16 04:16PM  BIOCEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Biocept Reports 2016 Third Quarter Financial Results PR Newswire
07:07AM  Q3 2016 Biocept Inc Earnings Release - After Market Close
Nov-04-16 04:22PM  BIOCEPT INC Files SEC form 8-K, Termination of a Material Definitive Agreement
Oct-31-16 08:05AM  Biocept to Release Third Quarter Financial Results and Host Investor Conference Call on November 9, 2016 PR Newswire -6.02%
Oct-28-16 05:18PM  BIOCEPT INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Trans
Oct-27-16 08:05AM  Biocept Appoints David Moskowitz Vice President, Strategy & Corporate Communications PR Newswire
Oct-26-16 08:03AM  GSK sees earnings rise amid good demand for vaccines +5.20%
Oct-20-16 08:05AM  Study Results Presented at the 2016 ESMO Annual Congress Demonstrate Leading Clinical Performance with Biocept's ctDNA Liquid Biopsy Platform vs. Tissue Biopsy PR Newswire
Oct-19-16 04:25PM  Biocept Announces Closing of $10 Million Public Offering of Common Stock and Warrants PR Newswire
Oct-18-16 09:48AM  ETFs with exposure to Biocept, Inc. : October 18, 2016
Oct-14-16 08:05AM  Biocept Announces Pricing of $10 Million Public Offering of Common Stock and Warrants PR Newswire -21.64%
Oct-05-16 08:05AM  /C O R R E C T I O N -- Biocept, Inc./ PR Newswire +5.19%
Oct-04-16 09:43AM  ETFs with exposure to Biocept, Inc. : October 4, 2016
Sep-29-16 09:01AM  BIOCEPT INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matter +200.20%
08:05AM  Clinical Results Demonstrating the Performance of Biocept's Target Selector Platform to be Presented at the 2016 European Society of Medical Oncology Annual Congress PR Newswire
Sep-23-16 10:02AM  ETFs with exposure to Biocept, Inc. : September 23, 2016
09:55AM  Biocept's Proprietary Liquid Biopsy Platform to be Featured at Two Upcoming Molecular Diagnostics Conferences PR Newswire
Sep-20-16 04:16AM  GSK names Emma Walmsley as new chief executive -5.00%
Sep-09-16 08:05AM  Biocept to Collaborate with Renowned Clinical Investigator Dr. Shilpa Gupta to Study the Utility of Liquid Biopsy Testing in Bladder and Prostate Cancers PR Newswire
Sep-01-16 08:05AM  Biocept Expands Chinese Patent Protection Covering Key Technologies for Circulating Tumor Cell Capture and Analysis Used in Liquid Biopsy Tests PR Newswire
Aug-30-16 08:05AM  Biocept Announces Agreement with Teneovita Medical to Market and Distribute its Liquid Biopsy Testing Platform in Canada PR Newswire
Aug-23-16 11:26AM  ETFs with exposure to Biocept, Inc. : August 23, 2016 +6.56%
Aug-18-16 08:05AM  Biocept to Present at Next Generation Dx Summit PR Newswire
Aug-12-16 02:10PM  ETFs with exposure to Biocept, Inc. : August 12, 2016 -7.94%
Aug-11-16 08:05AM  Biocept Expands Distribution of Liquid Biopsy Tests to the Philippines PR Newswire
Aug-09-16 12:57PM  Biocept, Inc. :BIOC-US: Earnings Analysis: Q2, 2016 By the Numbers : August 9, 2016
Aug-05-16 05:07PM  BIOCEPT INC Files SEC form 10-Q, Quarterly Report +6.56%
Aug-03-16 06:07AM  BIOCEPT INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Aug-02-16 08:14AM  BIOCEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits -17.11%
08:05AM  Biocept Reports 2016 Second Quarter Financial Results PR Newswire
07:07AM  Q2 2016 Biocept Inc Earnings Release - Before Market Open
Aug-01-16 04:18PM  BIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers +16.92%
10:23AM  Google sister company, drug maker to develop nerve implants
Jul-27-16 08:11AM  BIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits +6.35%
08:05AM  Biocept Appoints Timothy C. Kennedy as Chief Financial Officer and Senior Vice President of Operations PR Newswire
07:51AM  Pharmaceutical giant GSK invests in British sites
Jul-25-16 08:05AM  Biocept to Release Second Quarter Financial Results on August 2, 2016 and Host Investor Conference Call at 11:00 a.m. Eastern Time PR Newswire
Jul-21-16 01:49PM  ETFs with exposure to Biocept, Inc. : July 21, 2016
Jul-20-16 04:10PM  GlaxoSmithKline (Egypt) : Neutral outlook but great fundamentals
Jul-19-16 04:20PM  GlaxoSmithKline (Egypt): Price momentum supported by strong fundamentals
Jul-07-16 04:30PM  BIOCEPT INC Files SEC form 8-K, Change in Directors or Principal Officers
Jul-05-16 09:59AM  Biocept Gets Japanese Patent Covering Microchannel And Antibody Capture -7.46%
07:00AM  Biocept Granted Japanese Patent Covering Microchannel and Antibody Capture PR Newswire
Jun-29-16 04:11PM  BIOCEPT INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
07:00AM  Biocept Comments on Reimbursement Provisions in CMS' Final PAMA Rule PR Newswire
Jun-17-16 04:52PM  BIOCEPT INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Trans
Jun-06-16 08:19AM  Coverage initiated on Biocept by ROTH Capital
May-31-16 07:00AM  Biocept Launches Liquid Biopsy Immuno-Oncology PD-L1 Test PR Newswire
May-26-16 07:20PM  ETFs with exposure to Biocept, Inc. : May 26, 2016
04:01PM  BIOCEPT INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Trans
May-25-16 07:00AM  High Sensitivity of Biocept's Target Selector Blood-Based Liquid Biopsy Tests Featured in Two Abstracts at ASCO PR Newswire
May-23-16 07:00AM  Biocept Announces Master Services Agreement with Pharma Company to Develop Liquid Biopsy Tests PR Newswire
May-19-16 07:00AM  Biocept Launches Proprietary Liquid Biopsy Test to Detect RET Fusions in Patients with Lung Cancer PR Newswire
May-17-16 12:20PM  Biocept, Inc. :BIOC-US: Earnings Analysis: Q1, 2016 By the Numbers
May-13-16 04:39PM  BIOCEPT INC Files SEC form 10-Q, Quarterly Report -8.64%
May-12-16 04:18PM  BIOCEPT INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:05PM  Biocept Reports 2016 First Quarter Financial Results PR Newswire
07:07AM  Q1 2016 Biocept Inc Earnings Release - After Market Close
07:00AM  Biocept Expands Intellectual Property Portfolio with 12th Granted Patent on its Key Liquid Biopsy Technology PR Newswire
May-05-16 07:00AM  Biocept to Hold 2016 First Quarter Conference Call on May 12 PR Newswire
May-02-16 07:00AM  Biocept to Present at the Inaugural Joseph Gunnar PIONEERS 2016 Conference PR Newswire
Apr-29-16 04:44PM  BIOCEPT INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits EDGAR Online -21.43%
08:57AM  Biocept, Inc. Announces Pricing Of $5 Million Public Offering Of Common Stock And Warrants PR Newswire
Apr-28-16 04:53PM  Biocept Inc. Announces Proposed Public Offering Of Common Stock And Warrants PR Newswire
Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide an information to oncologists and other physicians that enable them to select personalized treatment for their patients based on detailed data on the characteristics of tumors. It offers assays for solid tumor indications, such as breast cancer, lung cancer, gastric cancer, colorectal cancer, prostate cancer, and melanoma. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Neff Edward A.DirectorOct 19Buy1.10227,272249,999289,735Oct 21 05:06 PM
HALE DAVID FDirectorOct 19Buy1.1090,909100,000109,099Oct 21 05:04 PM
Nall Michael W.CEO & PresidentOct 19Buy1.1036,36339,99949,575Oct 21 06:43 PM
Chandler Marsha AlpertDirectorOct 19Buy1.104,5455,0005,212Oct 21 06:18 PM
Kennedy TimothyCFO, Sr V.P. Operations & Sec.Oct 19Buy1.1036,36339,99961,363Oct 21 06:17 PM
HUEBNER BRUCE ADirectorOct 19Buy1.1020,00022,00024,000Oct 21 06:16 PM
Gerhardt BruceDirectorOct 19Buy1.1050,00055,00073,304Oct 21 06:15 PM
Singh VeenaSr VP & Sr Med DirectorOct 19Buy1.1010,00011,00026,666Oct 21 06:14 PM
ARNOLD LYLE JSR VP of R&D and CSOOct 19Buy1.1045,00049,50065,238Oct 21 06:12 PM
Wilson Margaret FayeDirectorOct 19Buy1.1013,63615,00025,067Oct 21 06:11 PM
Reiss Claire10% OwnerOct 19Buy1.10227,272249,9991,046,613Oct 21 06:06 PM